Table 1.

Available targeted agents in advanced gastric cancer

NCT code/trial name	Drugs		Setting	Masking	Primary endpoint	Arm	Status	Results
PhaseIIIToGA/NCT01041404	HER2 inhibitor	Trastuzumab	First line	Double blind	OS	Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo	Finished	Positive
PhaseIIINCT01774786		Pertuzumab	First line	Double blind	OS	Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab vs. Placebo	Ongoing	Unknown
Phase III/IIINCT01641939		T-DM1	Second line	Open label	OS	T-DM1 vs. Taxane	Ongoing	Unknown
PhaseIII TYTAN/NCT00486954		Lapatinib	Second line	Open label	OS	Lapatinib vs. Paclitaxel	Finished	Negative
PhaseIII LOGiC/NCT00680901		Lapatinib	First line	Double blind	OS	Capecitabine + oxaliplatin + Lapatinib vs. Placebo	Finished	Negative
PhaseIIIEXPAND/NCT00678535	EGFR Inhibitors	Cetuximab	First line	Open label	PFS	Capecitabine and cisplatin + Cetuximab vs. Placebo	Finished	Negative
PhaseIIIREAL-3/NCT01234324		Panitumumab	First line	Open label	Frequency of pT3/T4 categories after surgery	EOX (epirubicin/oxaliplatin/capecitabine)	Ongoing	Unknown
PhaseIII AVAGAST/NCT00548548	VEGF inhibitors	Bevacizumab	First line	Double blind	OS	Capecitabine + cisplatin + Bevacizumab vs. Placebo	Finished	Negative
PhaseIII REGARD/NCT00917384		Ramucirumab	Second line	Double blind	OS	and BSC + Ramucirumab vs. Placebo	Finished	Positive
PhaseIIIRAINBOW/NCT01170663		Ramucirumab	Second line	Double blind	OS	Paclitaxel + Ramucirumab vs. Placebo	Ongoing	Unknown
PhaseIIINCT01246960		Ramucirumab	First line	Double blind	PFS	mFOLFOX6+ Ramucirumab vs. Placebo	Ongoing	Unknown
PhaseIIINCT00970138		Apatinib	Third line	Double blind	PFS	Placebo vs.Apatinib	Finishes	Positive
PhaseIIINCT01512745		Apatinib	Third line	Double blind	PFS	placebo vs. apatinib	Ongoing	Unknown
PhaseIIINCT01747551		Aflibercept	First line	Double blind	PFS	mFOLFOX6 + Aflibercept vs. Placebo	Ongoing	Unknown
PhaseIIINCT01152645	c-MET inhibitor	Tivantinib (ARQ 197)	Second/Thirdline	Open label	DCR	Tivantinib	Finished	Modest efficacy
PhaseIIINCT01662869		Onartuzumab	First line	Double blind	OS	mFOLFOX6 + Onartuzumab vs. Placebo	Ongoing	Unknown
PhaseIIIGRANITE-1/NCT00879333	m-TOR inhibitor	Everolimus (RAD001)	Second/third line	Double blind	OS	Everolimus vs. Placebo	Finished	Negative

Abbreviation: HER2 human epidermal growth factor receptor-2, OS overall survival, EGFR epidermal growth factor receptor, PFS progression free survival, VEGF vascular endothelial growth factor, BSC best supportive care, DCR disease control rate, m-TOR mammalian target of rapamycinm.